DR. ADIB MOGHADDAM COMMENTS ON SCHWIND AMARIS

AMARIS_patient
TRANS-PRK WITH SCHWIND AMARIS TECHNOLOGY
2018-01-14
قوز قرنیه
TORIC ICL FOR TREATING KERATOCONUS
2018-03-03
دستگاه‌های SCHWIND AMARIS

With the SCHWIND AMARIS laser systems it is possible to carry out no-touch, all-laser surface ablations. The so-called TransPRK (Transepithelial Photorefractive Keratectomy) is an advanced version of surface treatments as LASEK, Epi-LASIK and PRK. Thereby the epithelium, which is the regenerative surface of the eye, is ablated by the laser system. The TransPRK is a transepithelial single-step treatment that avoids the eye coming into contact with any instrument. Now here is Dr.Adibmoghaddam’s comment: I have been using SCHWIND AMARIS for TransPRK treatment since 2010. Based on my experience, TransPRK is significantly superior in terms of clinical results and shows fewer complications compared to other laser-assisted vision correction methods. Better visual performance, predictability, safety and stability along with less pain, haze, aberration induction and other complications convinced me to consider TransPRK with the SCHWIND AMARIS platform as my treatment of choice for the majority of corneal laser ablation procedures. One of the outstanding characteristics of the SCHWIND AMARIS is its flexibility for modifications needed for each patient. This allows me to tailor an individualized treatment setting for each single eye (refined TransPRK) with satisfactory clinical results, giving me peace of mind. The comprehensive analysis of our patients’ data confirms the high predictability. It demonstrates excellent results for using TransPRK in myopic, high myopic, hyperopic and astigmatic cases. Notable numbers of the patients achieve outstanding vision after the treatment. Questionnaire-based data, as well as objective contrast sensitivity assessments, indicate enhanced quality of patients’ vison along with an improvement in quantitative indices. These results have been presented at various international ophthalmology conferences. As a leading TransPRK research group, we continuously gather, analyse and monitor clinical outcomes to provide new information and systematically upgrade our clinical knowledge.
For reading a comments click here!

Leave a Reply

Your email address will not be published. Required fields are marked *